Subcutaneous · GLP-1 / GIP dual
SYH2069
3 trials in this molecule. Source: ClinicalTrials.gov, as of November 5, 2026.
Trials
3
Ongoing
3
Recruiting
0
Completed
0
Sites
3
Countries
1
Endpoints
58
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
1
Phase 2
2
Trials by status
Not yet recruiting
2
Active, not recruiting
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
15
Glycemic / diabetes
13
Weight & body composition
12
Cardiometabolic biomarkers
11
Other (unclassified)
5
Renal / kidney
2
Top 20 metrics across this asset's endpoints
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
3 of 3
| Asset / Population | Eligibility highlight | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT07796477A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin | SYH2069, Tirzepatide Type 2 diabetes | BMI ≤40 | Ph 2 | Not yet recruiting | 1 | Sep 2027 | - | |
| NCT07736391A Study of SYH2069 Injection in Healthy Participants | SYH2069 Diabetes (other / unspecified), Obesity / overweight | BMI 19-28 | Ph 1 | Active, not recruiting | 1 | Jul 2026 | - | |
| NCT07803991Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes. | SYH2069 Obesity / overweight | BMI ≤40 | Ph 2 | Not yet recruiting | 1 | Sep 2027 | - |
Showing 1-3 of 3 trials